Prior to NAT, ultrasound-guided core needle biopsy (CNB) is commonly used to obtain the status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 in the lesions of patients with breast cancer. Here, ERBB2 is linked to breast carcinoma.